Developer docs
API playgroundTry for free, no card

Search company profiles

NanoCellect Biomedical

Full company profile

uuid0000v8j

Namestring
NanoCellect Biomedical
Legal namestring
NanoCellect Biomedical, Inc.
Websiteurl
nanocellect.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

NanoCellect Biomedical is a privately held life sciences instrumentation company headquartered in San Diego, California, that develops and commercializes microfluidic cell sorting platforms and consumables for biomedical research. The company's core technology uses low-pressure (<2 psi) piezoelectric actuation in disposable cartridges to gently sort cells — a deliberate contrast to traditional droplet-based electrostatic cell sorters that operate at higher pressures and can damage fragile cell types such as stem cells, induced pluripotent stem cells (iPSCs), primary neurons, and plant protoplasts.

The product portfolio centers on the WOLF G2 Cell Sorter (launched 2021), a benchtop dual-laser instrument supporting up to nine fluorescent colors, and the VERLO Image-Guided Cell Sorter (launched 2024), which combines flow cytometry with real-time image-based sorting across 12 imaging channels. Supporting offerings include the N1 Single-Cell Dispenser, CS1 Chiller-Stirrer, and CX2 Collection Cooler accessories, recurring consumables (disposable microfluidic cartridges and calibration beads), and tiered service contracts (Basic, Standard, Premium) plus Installation and Operational Qualification (IQ/OQ) services. Revenue is generated through a hybrid go-to-market: direct enterprise field sales for capital equipment, a global distributor network for international coverage, and an e-commerce shop for consumables. Customers include pharmaceutical and biotech firms (Takeda, Calico Life Sciences, contract development and manufacturing organizations), academic and medical research institutions (Mount Sinai, Rice University, Case Western Reserve University, UC Irvine, University of Michigan, Children's Hospital of Philadelphia), and cell therapy startups (Pluristyx), with applications spanning antibody discovery, cell line development, single-cell genomics, gene editing/CRISPR workflows, and stem cell research. The company has raised approximately $35M+ across disclosed rounds, most notably a $20M Series D led by Warburg Pincus in 2021 and a follow-on investment from Paladin Capital Group in 2023.

Short descriptiontext

NanoCellect Biomedical is a private San Diego biotech that develops microfluidic cell sorting instruments and consumables. Its WOLF G2 and VERLO platforms use low-pressure piezoelectric technology to gently sort fragile cells for pharmaceutical, biotech, and academic research customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microfluidic cell sorting, flow cytometry instruments, cell analysis systems, single-cell dispensing, lab automation equipment
Industry1 code
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Cell Sorting Instruments
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument Sales
TypeOne Time License
Description

Sale of WOLF G2 and VERLO cell sorter instruments along with accessories (N1 Single-Cell Dispenser, CS1 Chiller-Stirrer, CX2 Collection Cooler) as capital equipment purchases.

nanocellect.com
2Consumables
TypeHardware Sales
Description

Recurring revenue from disposable microfluidic cartridges (bulk and single-cell sorting) and calibration beads sold through web shop and quotes.

nanocellect.com
3Service Contracts
TypeSubscription Recurring
Description

Annual service contracts (Basic, Standard, Premium) covering instrument maintenance, preventive maintenance, priority support, training, and depot repair services.

nanocellect.com
4Qualification Services
TypeProfessional Services
Description

Installation Qualification (IQ) and Operational Qualification (OQ) services for regulatory compliance verification of WOLF G2 systems and accessories.

nanocellect.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details4 tiers
1WOLF G2 Cell Sorter - Quote-based pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Instruments sold as capital equipment with no public pricing; requires request for quote. Configurations available with different laser combinations (405/488nm, 488/561nm, 488/637nm, or single 488nm).

nanocellect.com
2VERLO Image-Guided Cell Sorter - Quote-based pricing
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Advanced image-guided cell sorter with two lasers and 12 imaging channels. Pricing not publicly disclosed.

nanocellect.com
3Microfluidic Cartridges - Pack pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Bulk Sorting Cartridge Pack of 3 (Part 150404) and Pack of 10 (Part 150410). Single-Cell Sorting Cartridge Pack of 3 (Part 150405) and Pack of 10 (Part 150411). Requires quote request.

nanocellect.com
4Service Contracts - Three tiers
ModelSubscriptionBilling cadenceAnnual
Notes

Basic: unlimited remote support, replacement parts, travel included. Standard: adds preventive maintenance (1/year). Premium: priority support, unlimited training, additional on-site training, depot repair, loaner unit, applications support.

nanocellect.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1WOLF G2
Description

Benchtop microfluidic cell sorter with two lasers and up to nine colors for gentle cell sorting in research applications.

nanocellect.com
+6 more records
Core offering1 text field

NanoCellect develops, manufactures, and commercializes microfluidic cell sorting instruments (WOLF G2 and VERLO Image-Guided Cell Sorter) that use low-pressure (<2 psi) piezoelectric actuation in disposable cartridges for gentle, contamination-free cell sorting. The company sells the instruments, supporting accessories (N1 Single-Cell Dispenser, CS1 Chiller-Stirrer, CX2 Collection Cooler), consumables (microfluidic cartridges and calibration beads), and service contracts to academic, pharmaceutical, and biotech research customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Up to 93% single-cell plating efficiency for iPSCs compared to lower efficiency with non-sorting methods
+6 more records
Product overview1 text field

NanoCellect Biomedical offers a family of microfluidic cell sorting instruments centered on gentle, low-pressure sorting technology. The core product portfolio consists of the WOLF G2 Cell Sorter (entry-level microfluidic benchtop sorter with dual lasers and up to nine colors) and the VERLO Image-Guided Cell Sorter (advanced imaging flow cytometry platform combining label-free and fluorescent detection with image-based cell sorting). Key accessories include the N1 Single-Cell Dispenser for plate-based single-cell deposition, the CS1 Chiller-Stirrer for temperature-sensitive samples, and the CX2 Collection Cooler for post-sort sample preservation. Supporting consumables include microfluidic cartridges (bulk and single-cell configurations) and calibration beads. Service offerings encompass Basic, Standard, and Premium service contracts with preventative maintenance options, plus Installation and Operational Qualification (IQ/OQ) services. Educational resources include Lunch & Learn sessions.

Product and service9 records
1VERLO Image-Guided Cell Sorter
Categorycore product
Description

World's first two-laser image-guided cell sorter combining conventional flow cytometry with imaging technology. Features 9 fluorescent channels, 3 label-free channels, and 12 imaging channels total, enabling visualization, analysis and sorting based on cell morphology, subcellular localization, and cell-cell interactions. Targeted at biomedical researchers needing morphology-based sorting.

2WOLF G2 Cell Sorter
Categorycore product
Description

Benchtop microfluidic cell sorter featuring dual lasers and up to nine fluorescent colors. Operates at less than 2 psi for gentle cell sorting, preserving cell viability and integrity. Supports both bulk sorting and single-cell dispensing into 96- or 384-well plates via the N1 accessory. Targeted at academic, pharmaceutical, and biotech researchers.

3N1 Single-Cell Dispenser
Categoryadd-on/accessory
Description

Accessory module for WOLF cell sorters enabling single-cell deposition into 96- or 384-well plates. Provides higher rates of singlet detection compared to cell printers or limiting dilution methods, with deposition volumes of 3-10 µL per well.

4CS1 Chiller-Stirrer
5CX2 Collection Cooler
6Microfluidic Cartridges
7Calibration Beads
8Service Contracts (Basic, Standard, Premium)
9Installation and Operational Qualification (IQ/OQ)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Professor Yuhwa Lo, PhD (UC San Diego)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founder and Chairman of NanoCellect's Scientific Advisory Board. Near 20 years of collaboration with Professor Lo has been awarded over $13 million in NIH SBIR Awards. His research expertise in microfluidics and biomedical engineering has been foundational to the company's technology development.

nanocellect.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Becton Dickinson's life-sciences arm manufactures the FACSDiscover, FACSymphony, and FACSAria cell sorters and is the dominant incumbent in flow cytometry. BD directly competes with NanoCellect in cell sorting and is now extending into image-enabled sorting (BD CellView), making it the most direct peer.

TypeDirect peer
Description

A Danaher operating company shipping the MoFlo Astrios, CytoFLEX S, and Navios flow cytometers/sorters. Competes head-to-head with NanoCellect across academic and pharma research labs, particularly in cell line development and immunology workflows.

3Sony Biotechnology
TypeDirect peer
Description

Sony's life-sciences subsidiary markets the SH800, MA900, and CGX10 cell sorters targeting single-cell sorting workflows. Directly comparable to the WOLF G2 in benchtop form factor and use cases such as stem cell and antibody discovery sorting.

TypeDirect peer
Description

Cytek offers the Aurora and Northern Lights spectral flow cytometers and the Cytek Aurora CS cell sorter, widely adopted in academic and pharma immunology and cell therapy labs. A direct peer in the gentle, high-content flow cytometry space NanoCellect targets.

TypeDirect peer
Description

Formerly Fluidigm, Standard BioTools markets the Hyperion XTi imaging mass cytometer and the CyTOF XT — both imaging-based single-cell platforms. Comparable to NanoCellect's VERLO strategy of combining imaging with high-content single-cell analysis.

TypeBroad incumbent
Description

Thermo Fisher sells the Invitrogen Attune NxT flow cytometer and a broad portfolio of cell analysis reagents and instruments. Overlaps with NanoCellect in cell sorting and flow cytometry but as part of a much larger life-sciences tools portfolio.

TypeBroad incumbent
Description

Agilent is a strategic investor in NanoCellect via Agilent Ventures and also operates the Seahorse and cell-analysis portfolio plus the recently acquired Resolution Bioscience/Olaris assets. A broad incumbent adjacent to NanoCellect in cell line development analytics.

TypeEmerging player
Description

Applied Cells' MARS (Magnetic-Reduced Shear) rare-cell sorting technology is a documented NanoCellect partner. Comparable as a smaller, emerging player in gentle/rare-cell isolation that intersects with NanoCellect's fragile-cell-sorting niche.

TypeEmerging player
Description

Cytovale develops rapid cell-based diagnostic platforms (IntelliSep) using deformability cytometry. Adjacent to NanoCellect in applying novel cell-measurement modalities to clinical and research workflows.

TypeOthers
Description

10x Genomics is a downstream single-cell genomics platform partner (Chromium, Visium) with which NanoCellect co-markets WOLF-based sample preparation. Not a direct competitor but a key ecosystem partner for NanoCellect's genomics customer segment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NanoCellect Biomedical

Cell Sorting Instrumentsnanocellect.com

NanoCellect Biomedical is a private San Diego biotech that develops microfluidic cell sorting instruments and consumables. Its WOLF G2 and VERLO platforms use low-pressure piezoelectric technology to gently sort fragile cells for pharmaceutical, biotech, and academic research customers.

What NanoCellect Biomedical does

NanoCellect Biomedical is a privately held life sciences instrumentation company headquartered in San Diego, California, that develops and commercializes microfluidic cell sorting platforms and consumables for biomedical research. The company's core technology uses low-pressure (<2 psi) piezoelectric actuation in disposable cartridges to gently sort cells — a deliberate contrast to traditional droplet-based electrostatic cell sorters that operate at higher pressures and can damage fragile cell types such as stem cells, induced pluripotent stem cells (iPSCs), primary neurons, and plant protoplasts.

The product portfolio centers on the WOLF G2 Cell Sorter (launched 2021), a benchtop dual-laser instrument supporting up to nine fluorescent colors, and the VERLO Image-Guided Cell Sorter (launched 2024), which combines flow cytometry with real-time image-based sorting across 12 imaging channels. Supporting offerings include the N1 Single-Cell Dispenser, CS1 Chiller-Stirrer, and CX2 Collection Cooler accessories, recurring consumables (disposable microfluidic cartridges and calibration beads), and tiered service contracts (Basic, Standard, Premium) plus Installation and Operational Qualification (IQ/OQ) services. Revenue is generated through a hybrid go-to-market: direct enterprise field sales for capital equipment, a global distributor network for international coverage, and an e-commerce shop for consumables. Customers include pharmaceutical and biotech firms (Takeda, Calico Life Sciences, contract development and manufacturing organizations), academic and medical research institutions (Mount Sinai, Rice University, Case Western Reserve University, UC Irvine, University of Michigan, Children's Hospital of Philadelphia), and cell therapy startups (Pluristyx), with applications spanning antibody discovery, cell line development, single-cell genomics, gene editing/CRISPR workflows, and stem cell research. The company has raised approximately $35M+ across disclosed rounds, most notably a $20M Series D led by Warburg Pincus in 2021 and a follow-on investment from Paladin Capital Group in 2023.

NanoCellect Biomedical firmographics

Firmographics
Name
NanoCellect Biomedical
Legal name
NanoCellect Biomedical, Inc.
Website
https://nanocellect.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
NanoCellect Biomedical is a private San Diego biotech that develops microfluidic cell sorting instruments and consumables. Its WOLF G2 and VERLO platforms use low-pressure piezoelectric technology to gently sort fragile cells for pharmaceutical, biotech, and academic research customers.
Ownership category
akta.pro rank

NanoCellect Biomedical industry classification

Industry
Product category
Cell Sorting Instruments
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Microfluidic cell sorting
  • Flow cytometry instruments
  • Cell analysis systems
  • Single-cell dispensing
  • Lab automation equipment

Where NanoCellect Biomedical is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NanoCellect Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Instrument Sales: Sale of WOLF G2 and VERLO cell sorter instruments along with accessories (N1 Single-Cell Dispenser, CS1 Chiller-Stirrer, CX2 Collection Cooler) as capital equipment purchases.
  2. Consumables: Recurring revenue from disposable microfluidic cartridges (bulk and single-cell sorting) and calibration beads sold through web shop and quotes.
  3. Service Contracts: Annual service contracts (Basic, Standard, Premium) covering instrument maintenance, preventive maintenance, priority support, training, and depot repair services.
  4. Qualification Services: Installation Qualification (IQ) and Operational Qualification (OQ) services for regulatory compliance verification of WOLF G2 systems and accessories.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goWOLF G2 Cell Sorter - Quote-based pricing
One time/ perpetual licensePay-as-you-goVERLO Image-Guided Cell Sorter - Quote-based pricing
Unit PricingPay-as-you-goMicrofluidic Cartridges - Pack pricing
SubscriptionAnnualService Contracts - Three tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

NanoCellect Biomedical product offering

Product offering

Core offering

NanoCellect develops, manufactures, and commercializes microfluidic cell sorting instruments (WOLF G2 and VERLO Image-Guided Cell Sorter) that use low-pressure (<2 psi) piezoelectric actuation in disposable cartridges for gentle, contamination-free cell sorting. The company sells the instruments, supporting accessories (N1 Single-Cell Dispenser, CS1 Chiller-Stirrer, CX2 Collection Cooler), consumables (microfluidic cartridges and calibration beads), and service contracts to academic, pharmaceutical, and biotech research customers.

Product overview

NanoCellect Biomedical offers a family of microfluidic cell sorting instruments centered on gentle, low-pressure sorting technology. The core product portfolio consists of the WOLF G2 Cell Sorter (entry-level microfluidic benchtop sorter with dual lasers and up to nine colors) and the VERLO Image-Guided Cell Sorter (advanced imaging flow cytometry platform combining label-free and fluorescent detection with image-based cell sorting). Key accessories include the N1 Single-Cell Dispenser for plate-based single-cell deposition, the CS1 Chiller-Stirrer for temperature-sensitive samples, and the CX2 Collection Cooler for post-sort sample preservation. Supporting consumables include microfluidic cartridges (bulk and single-cell configurations) and calibration beads. Service offerings encompass Basic, Standard, and Premium service contracts with preventative maintenance options, plus Installation and Operational Qualification (IQ/OQ) services. Educational resources include Lunch & Learn sessions.

Differentiator

Problem solved

Functional benefit

Brands

  • WOLF G2: Benchtop microfluidic cell sorter with two lasers and up to nine colors for gentle cell sorting in research applications.
  • VERLO
  • N1 Single-Cell Dispenser
  • CS1 Chiller-Stirrer
  • CX2 Collection Cooler
  • WOLFViewer
  • WOLF Spectra Viewer

Products and services

  • VERLO Image-Guided Cell Sorter World's first two-laser image-guided cell sorter combining conventional flow cytometry with imaging technology. Features 9 fluorescent channels, 3 label-free channels, and 12 imaging channels total, enabling visualization, analysis and sorting based on cell morphology, subcellular localization, and cell-cell interactions. Targeted at biomedical researchers needing morphology-based sorting.
  • WOLF G2 Cell Sorter Benchtop microfluidic cell sorter featuring dual lasers and up to nine fluorescent colors. Operates at less than 2 psi for gentle cell sorting, preserving cell viability and integrity. Supports both bulk sorting and single-cell dispensing into 96- or 384-well plates via the N1 accessory. Targeted at academic, pharmaceutical, and biotech researchers.
  • N1 Single-Cell Dispenser Accessory module for WOLF cell sorters enabling single-cell deposition into 96- or 384-well plates. Provides higher rates of singlet detection compared to cell printers or limiting dilution methods, with deposition volumes of 3-10 µL per well.
  • CS1 Chiller-Stirrer
  • CX2 Collection Cooler
  • Microfluidic Cartridges
  • Calibration Beads
  • Service Contracts (Basic, Standard, Premium)
  • Installation and Operational Qualification (IQ/OQ)

Quantifiable outcome

  • Up to 93% single-cell plating efficiency for iPSCs compared to lower efficiency with non-sorting methods
  • +6 more outcomes

Companies that use NanoCellect Biomedical

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles4 records

NanoCellect Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

NanoCellect Biomedical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Professor Yuhwa Lo, PhD (UC San Diego)coreStrategic or Co-development PartnerCo-founder and Chairman of NanoCellect's Scientific Advisory Board. Near 20 years of collaboration with Professor Lo has been awarded over $13 million in NIH SBIR Awards. His research expertise in microfluidics and biomedical engineering has been foundational to the company's technology development.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

NanoCellect Biomedical competitors and assessment

Company assessment

Direct peers

  • BD Biosciences: Becton Dickinson's life-sciences arm manufactures the FACSDiscover, FACSymphony, and FACSAria cell sorters and is the dominant incumbent in flow cytometry. BD directly competes with NanoCellect in cell sorting and is now extending into image-enabled sorting (BD CellView), making it the most direct peer.
  • Beckman Coulter Life Sciences: A Danaher operating company shipping the MoFlo Astrios, CytoFLEX S, and Navios flow cytometers/sorters. Competes head-to-head with NanoCellect across academic and pharma research labs, particularly in cell line development and immunology workflows.
  • Sony Biotechnology: Sony's life-sciences subsidiary markets the SH800, MA900, and CGX10 cell sorters targeting single-cell sorting workflows. Directly comparable to the WOLF G2 in benchtop form factor and use cases such as stem cell and antibody discovery sorting.
  • Cytek Biosciences: Cytek offers the Aurora and Northern Lights spectral flow cytometers and the Cytek Aurora CS cell sorter, widely adopted in academic and pharma immunology and cell therapy labs. A direct peer in the gentle, high-content flow cytometry space NanoCellect targets.
  • Standard BioTools: Formerly Fluidigm, Standard BioTools markets the Hyperion XTi imaging mass cytometer and the CyTOF XT — both imaging-based single-cell platforms. Comparable to NanoCellect's VERLO strategy of combining imaging with high-content single-cell analysis.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher sells the Invitrogen Attune NxT flow cytometer and a broad portfolio of cell analysis reagents and instruments. Overlaps with NanoCellect in cell sorting and flow cytometry but as part of a much larger life-sciences tools portfolio.
  • Agilent Technologies: Agilent is a strategic investor in NanoCellect via Agilent Ventures and also operates the Seahorse and cell-analysis portfolio plus the recently acquired Resolution Bioscience/Olaris assets. A broad incumbent adjacent to NanoCellect in cell line development analytics.

Emerging players

  • Applied Cells: Applied Cells' MARS (Magnetic-Reduced Shear) rare-cell sorting technology is a documented NanoCellect partner. Comparable as a smaller, emerging player in gentle/rare-cell isolation that intersects with NanoCellect's fragile-cell-sorting niche.
  • Cytovale: Cytovale develops rapid cell-based diagnostic platforms (IntelliSep) using deformability cytometry. Adjacent to NanoCellect in applying novel cell-measurement modalities to clinical and research workflows.

Others

  • 10x Genomics: 10x Genomics is a downstream single-cell genomics platform partner (Chromium, Visium) with which NanoCellect co-markets WOLF-based sample preparation. Not a direct competitor but a key ecosystem partner for NanoCellect's genomics customer segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

NanoCellect Biomedical social profiles

Digital presence

NanoCellect Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NanoCellect Biomedical leadership team

Management profile

Number of profiles

Profiles6 records

NanoCellect Biomedical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NanoCellect Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoCellect Biomedical

What does NanoCellect Biomedical do?

NanoCellect develops, manufactures, and commercializes microfluidic cell sorting instruments (WOLF G2 and VERLO Image-Guided Cell Sorter) that use low-pressure (<2 psi) piezoelectric actuation in disposable cartridges for gentle, contamination-free cell sorting. The company sells the instruments, supporting accessories (N1 Single-Cell Dispenser, CS1 Chiller-Stirrer, CX2 Collection Cooler), consumables (microfluidic cartridges and calibration beads), and service contracts to academic, pharmaceutical, and biotech research customers.

Is NanoCellect Biomedical a public or private company?

NanoCellect Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was NanoCellect Biomedical founded?

NanoCellect Biomedical was founded in 2011. It employs 11 to 50 people.

Where is NanoCellect Biomedical based?

NanoCellect Biomedical is headquartered in San Diego, United States, in the North America region.

How does NanoCellect Biomedical make money?

Four revenue lines are on record. Instrument Sales are the primary driver. The others are consumables, service Contracts and qualification Services.

Who are NanoCellect Biomedical's main competitors?

Direct peers on record are BD Biosciences, Beckman Coulter Life Sciences, Sony Biotechnology, Cytek Biosciences and Standard BioTools. Broad incumbents are Thermo Fisher Scientific and Agilent Technologies. Emerging players are Applied Cells and Cytovale. 10x Genomics is listed as an others.

Does NanoCellect Biomedical have an API?

No public API is recorded for NanoCellect Biomedical.

What industry is NanoCellect Biomedical in?

NanoCellect Biomedical's product category is Cell Sorting Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 3345 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsNova Biomedical Acquires NanoCellect Assets to Expand Cell Line Development PortfolioNova Biomedical acquired NanoCellect's microfluidic cell sorting assets, adding the WOLF G2 platform to its portfolio. The integration with Nova's Solentim and analytical tools aims to accelerate cell line development and improve clone selection. The company expects this to strengthen its connected bioprocessing platform.FinanzNachrichten.deEQS-News: Nova Biomedical treibt integrierte Arbeitsabläufe für die Zelllinienentwicklung voran: Die Produkte von NanoCellect gehören jetzt zu Nova BiomedicalNova Biomedical announced the acquisition of certain assets from NanoCellect, a provider of microfluidic cell sorting technology, expanding its cell line development capabilities. The NanoCellect WOLF G2 platform will complement Nova Biomedical's existing Solentim portfolio for cloning, verification, and growth analysis, enabling an integrated approach that links cell selection, single-cell isolation, and high-reliability clonal verification. This portfolio expansion is expected to accelerate cell line development timelines and improve clone selection outcomes while providing a stronger foundation for process development, scale-up, and manufacturing.PR NewswireNova Biomedical breidt geïntegreerde workflows voor de ontwikkeling van cellijnen uit: NanoCellect-producten maken nu deel uit van Nova BiomedicalNova Biomedical announced a transaction to acquire certain assets from NanoCellect, a supplier of microfluidic technology for cell sorting. The acquisition adds NanoCellect's WOLF G2 cell sorting platform to Nova Biomedical's existing Solentim portfolio, creating a more integrated approach to cell line development that connects cell selection, single-cell isolation, and reliable clone verification. The company states this expansion will shorten cell line development timelines and strengthen the foundation for process development, scale-up, and production in biopharmaceutical workflows.PR NewswireNova Biomedical treibt integrierte Arbeitsabläufe für die Zelllinienentwicklung voran: Die Produkte von NanoCellect gehören jetzt zu Nova BiomedicalNova Biomedical announced on July 25, 2026 the acquisition of certain assets from NanoCellect, a microfluidic cell sorting technology provider, expanding its cell line development capabilities for the biopharmaceutical industry. The deal incorporates NanoCellect's WOLF G2 cell sorting platform into Nova Biomedical's existing Solentim portfolio, which already includes tools for clonal verification, growth analysis, cell culture monitoring, and osmolality measurement. This integration aims to accelerate cell line development timelines and improve clone selection outcomes by linking cell selection, single-cell isolation, and high-reliability clonal verification across the bioprocessing workflow.PR NewswireNova Biomedical fait progresser les processus intégrés de développement de lignées cellulaires : les produits de NanoCellect entrent dans la gamme de Nova BiomedicalNova Biomedical announced the acquisition of certain assets from NanoCellect, a microfluidic cell sorting technology provider, expanding its capabilities in cell line development for biopharmaceutical processes. The deal integrates NanoCellect's WOLF G2® cell sorting platform with Nova's existing Solentim portfolio for clone generation, verification, and growth analysis. This acquisition aims to reduce cell line development timelines and improve clonal selection outcomes while strengthening Nova Biomedical's integrated bioprocess offering.PR Newswire APACNova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova BiomedicalNova Biomedical announced a transaction involving certain assets of NanoCellect, a microfluidic cell sorting technology provider, expanding its capabilities in cell line development for biopharmaceutical workflows. The NanoCellect WOLF G2 cell sorting platform will complement Nova's existing Solentim portfolio for clone generation, verification, and growth analysis, enabling a more integrated approach from cell selection through manufacturing. This portfolio expansion is intended to accelerate cell line development timelines and strengthen Nova Biomedical's position in the bioprocessing lifecycle.PR NewswireNova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova BiomedicalNova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology, expanding its capabilities in cell line development for biopharmaceutical workflows. The acquisition integrates NanoCellect's WOLF G2 cell sorting platform with Nova's existing Solentim portfolio, enabling a more connected approach to cell selection, single-cell isolation, and clone verification. This portfolio expansion aims to accelerate cell line development timelines and improve clone selection outcomes across the bioprocessing lifecycle from early development through manufacturing.YahooNova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova BiomedicalNova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This acquisition expands Nova Biomedical's capabilities in cell line development by integrating NanoCellect’s WOLF G2 platform with its existing Solentim portfolio to create more integrated biopharmaceutical workflows.PR NewswireNanoCellect Launches VERLO: First Demonstration of Image-Based Sorting of Interacting Immune Synapsed Cells Followed by Confirmation of Immune FunctionalityNanoCellect Biomedical launched the VERLO Image-Guided Cell Sorter, a new microfluidic device that integrates brightfield imaging with fluorescent detection to sort interacting immune cells. The system was unveiled at the CYTO 2024 conference in Edinburgh and is designed to support research in immuno-oncology, stem cells, and cell therapies by enabling precise single-cell visualization without labeling.BioinformantHow NanoCellect is Revolutionizing Cell Analysis and Sorting for Stem Cells (and Other Fragile Samples)NanoCellect Biomedical is revolutionizing cell analysis and sorting through its WOLF Cell Sorter, a microfluidic-based device designed to handle fragile samples like stem cells with higher viability and minimal contamination. The company has secured significant funding from NIH SBIR grants and investors including FusionX Ventures, Illumina Ventures, and Agilent Technologies to support its transition from R&D to commercial operations. NanoCellect serves key markets in single-cell genomics, gene editing, and antibody therapeutics, while maintaining strategic partnerships with companies such as 10x Genomics and QIAGEN.